Northwestern University Feinberg School of Medicine
Evanston, IL, United States
Dr. Ruderman received his undergraduate degree in English literature from Princeton University and his medical degree from the Albert Einstein College of Medicine. After a residency in internal medicine at the Hospital of the University of Pennsylvania, he completed a rheumatology fellowship at Brigham and Women’s Hospital, with a concurrent research fellowship at the Harvard School of Public Health. He joined the faculty at Northwestern University in 2000, where he is currently a Professor of Medicine and Associate Chief for Clinical Affairs of the Division of Rheumatology. He is co-director of a cooperative clinic for the management of psoriasis and psoriatic arthritis.
Dr. Ruderman is a past president of the Chicago Rheumatism Society. He has served as principal investigator on over 50 clinical trials, and he is involved in several projects that link clinical practice and the research agenda in the rheumatology clinic. He also serves on the data safety monitoring boards for several international, multicenter, clinical trials in rheumatology. In addition to his research efforts, Dr. Ruderman serves as a chair of Northwestern University’s institutional review board. He currently serves as the ACR liaison to the executive committee of the Association of Rheumatology Professionals, is a past member of the Scientific Advisory Council of the Rheumatology Research Foundation, and is the Deputy Editor-in-Chief of the Journal of Rheumatology.
Navigating Biologics in Spondyloarthritis
Friday, October 24, 2025
4:10 PM – 4:30 PM Central Time
Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Terminated); Janssen: Advisor or Review Panel Member (Ongoing); Merck/MSD: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Advisor or Review Panel Member (Ongoing); Takeda: Consultant (Ongoing); UCB: Consultant (Ongoing)
Navigating Biologics in Spondyloarthritis
Friday, October 24, 2025
4:30 PM – 4:50 PM Central Time
Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Terminated); Janssen: Advisor or Review Panel Member (Ongoing); Merck/MSD: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Advisor or Review Panel Member (Ongoing); Takeda: Consultant (Ongoing); UCB: Consultant (Ongoing)
Navigating Biologics in Spondyloarthritis
Friday, October 24, 2025
4:50 PM – 5:10 PM Central Time
Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Terminated); Janssen: Advisor or Review Panel Member (Ongoing); Merck/MSD: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Advisor or Review Panel Member (Ongoing); Takeda: Consultant (Ongoing); UCB: Consultant (Ongoing)
Navigating Biologics in Spondyloarthritis
Friday, October 24, 2025
5:10 PM – 5:30 PM Central Time
Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Terminated); Janssen: Advisor or Review Panel Member (Ongoing); Merck/MSD: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing); NS Pharma: Advisor or Review Panel Member (Ongoing); Takeda: Consultant (Ongoing); UCB: Consultant (Ongoing)
